Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending June 12, 2018. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them. It does not contain financial results, operational updates, or strategic commentary for the company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure of specific share transactions and does not report consolidated financial performance.
Material Changes and Transaction Details
The filing discloses a series of identical share acquisition transactions executed on June 11, 2018, on the London Stock Exchange (XLON). The transactions were conducted under the Company's Share Reward Plan.
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Type: Acquisition of Ordinary Shares.
- Price: £15.4154 per share.
- Volume per Executive: 16 Ordinary Shares (comprising 8 partnership shares and 8 matching shares).
- Executives Involved:
- Ms E Walmsley (Chief Executive Officer)
- Mr R G Connor (President, Global Manufacturing & Supply)
- Mr S Dingemans (Chief Financial Officer)
- Mr N Hirons (SVP, Global Ethics & Compliance)
- Mr L Miels (President, Global Pharmaceuticals)
- Mr D S Redfern (Chief Strategy Officer)
- Ms C Thomas (SVP, Human Resources)
- Mr P C Thomson (President, Global Affairs)
- Mrs V A Whyte (Company Secretary)
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the statutory notification of the share acquisitions listed above.
Key Facts for Investor Verification
- Verify the total number of shares acquired by each executive against the company's broader share ownership reports.
- Confirm the share price of £15.4154 aligns with the market price on the London Stock Exchange for June 11, 2018.
- Note that these transactions are part of a standard Share Reward Plan and do not represent open market purchases or sales by the executives.
- Recognize that this filing contains no financial performance data; refer to the company's Form 20-F or interim reports for revenue and profit metrics.